Promising combo for brain metastases? trial ends early

NCT ID NCT04791384

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested two oral drugs, abemaciclib and elacestrant, in women with a type of breast cancer (HR+/HER2-) that had spread to the brain. The goal was to see if the combination was safe and could shrink brain tumors. However, the study was stopped early after enrolling only 5 people, so we have very little information about how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
abemaciclib (Verzenio) and elacestrant
What this could lead to
If successful, this combination could offer a new oral treatment option for breast cancer that has spread to the brain, potentially controlling the disease and improving outcomes.
What could go wrong
The trial was terminated early with only 5 participants, so results are very limited. It is unclear if the combination is safe or effective, and it may not work for others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Care Northwest

    Spokane Valley, Washington, 99216, United States

  • Duke Cancer Center

    Durham, North Carolina, 27710, United States

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida, 33140, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.